학술논문
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Document Type
Article
Author
Saussele, S.; Fabarius, A.; Hofmann, W.-K.; Richter, J.; Guilhot, J.; Gruber, F.X.; Hjorth-Hansen, H.; Almeida, A.; Janssen, J.J.W.M.; Mayer, J.; Koskenvesa, P.; Mustjoki, S.; Panayiotidis, P.; Olsson-Strömberg, U.; Martinez-Lopez, J.; Rousselot, P.; Vestergaard, H.; Ehrencrona, H.; Kairisto, V.; Machová Poláková, K.; Müller, M.C.; Berger, M.G.; Hochhaus, A.; Pfirrmann, M.; Mahon, F.-X.; Ossenkoppele, G.; Pagoni, M.N.; Söderlund, S.; Escoffre-Barbe, M.; Etienne, G.; Dengler, J.; Huguet, F.; von Bubnoff, N.; Klamova, H.; Faber, E.; Guilhot, F.; Lotfi, K.; Rea, D.; Brümmendorf, T.H.; de Greef, G.E.; Stenke, L.; Nicolini, F.E.; Legros, L.; Burchert, A.; Voglova, J.; Charbonnier, A.; Gyan, E.; Kunzmann, V.; Westerweel, P.E.
Source
In: The Lancet Oncology . (The Lancet Oncology, June 2018, 19(6):747-757)
Subject
Language
English
ISSN
14745488
14702045
14702045